Insider Trading November 18, 2026 10:00 PM

Stereotaxis Director Menawat Discloses $99,983 Stock Purchase

The board member acquired 121,561 shares at $0.8225, lifting his direct stake to 1,157,121 shares as the stock trades at $0.95.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
STXS

Stereotaxis director Arun Menawat has disclosed the purchase of 121,561 shares of company common stock at $0.8225 per share, for a total of approximately $99,983. The transaction, reported in a Form 4 filing with the Securities and Exchange Commission, occurred on November 17, 2026, and was signed on November 18, 2026, by Kimberly R. Peery, Attorney-in-Fact. Following the acquisition, Menawat directly holds 1,157,121 shares. The insider purchase comes as Stereotaxis stock trades at $0.95, down 45% over the past six months, and as the company, with a market cap of $95.42 million, is described as quickly burning through cash according to an analysis. The company recently reported third-quarter earnings that showed a larger-than-expected adjusted loss of $0.07 per share versus analysts' expectations of a $0.05 loss, and revenue of $8.9 million that missed the anticipated $9.93 million despite a 20% increase from the previous year. Management highlighted advancements in new products and expressed optimism about achieving profitability in the upcoming year.

Stereotaxis Director Menawat Discloses $99,983 Stock Purchase
STXS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Arun Menawat bought 121,561 Stereotaxis shares at $0.8225 per share, for a total of approximately $99,983, raising his direct holdings to 1,157,121 shares.
  • The purchase occurred as Stereotaxis stock trades at $0.95, down 45% over six months, and as the company, with a $95.42 million market cap, is described as quickly burning through cash.
  • The insider transaction follows third-quarter results that showed an adjusted loss of $0.07 per share versus expectations of a $0.05 loss, and revenue of $8.9 million that missed the $9.93 million forecast despite 20% year-over-year growth.

Stereotaxis, Inc. (NASDAQ:STXS) director Arun Menawat has reported a direct acquisition of company common stock, according to a Form 4 filing submitted to the Securities and Exchange Commission. The transaction took place on November 17, 2026.

Menawat purchased 121,561 shares at a price of $0.8225 per share, for a total value of approximately $99,983. As a result of the purchase, his direct holdings in Stereotaxis common stock now stand at 1,157,121 shares. The filing was signed by Kimberly R. Peery, Attorney-in-Fact for Arun S. Menawat, on November 18, 2026.

The disclosure arrives at a time when Stereotaxis shares are trading at $0.95. The stock has declined 45% over the past six months. The company carries a market capitalization of $95.42 million and, according to an analysis, is quickly burning through cash. That analysis also highlights six additional key tips for investors evaluating the medical device maker.

Separately, Stereotaxis recently reported third-quarter earnings that showed a larger-than-expected loss and revenue that fell short of Wall Street forecasts. The company recorded an adjusted loss of $0.07 per share, compared with analysts' expectations of a $0.05 loss. Revenue reached $8.9 million, missing the anticipated $9.93 million, even though it represented a 20% increase from the previous year.

Management highlighted advancements in new products and expressed optimism about achieving profitability in the upcoming year. These developments have been closely watched by investors and analysts alike.

The Form 4 disclosure provides a factual account of the director's direct ownership change. It does not include any statement from Menawat regarding his reasons for the purchase, nor does it offer guidance on future transactions. The filing is a standard regulatory notification of insider activity and should be read alongside the company's broader financial disclosures.

For investors tracking Stereotaxis, the insider purchase and the recent quarterly results represent two distinct data points. The purchase reflects a change in a director's direct holdings, while the earnings report details the company's recent financial performance against analyst expectations. Both are part of the public record available to market participants.

Risks

  • Stereotaxis reported a larger-than-expected quarterly loss and revenue that fell short of analyst forecasts, which may raise concerns about its near-term financial performance.
  • The company is described as quickly burning through cash, a factor that could affect its financial flexibility.
  • The stock has declined 45% over the past six months and trades at $0.95, reflecting recent market pressure on the shares.

More from Insider Trading

Jack Henry Accounting Chief Swearingen Sells $159,695 in Stock, Gifts Shares Nov 18, 2026 Revolution Medicines Insider Sale: Stephen Kelsey Offloads $4.5 Million in Stock Nov 18, 2026 PubMatic Accounting Chief Gimbel Offloads $27,887 in Shares to Cover RSU Tax Bill Nov 18, 2026 Constellation Brands 10% Holder AJB Business Holdings Offloads 75,000 Shares for $10.88 Million Nov 18, 2026 Figma Director Radakovich Offloads $395K in Stock Near 52-Week Low Nov 18, 2026